SOURCE: Xtalks

Xtalks Webinars

October 26, 2015 15:00 ET

Top News Stories You Might Have Missed From Xtalks

Xtalks Provides Current Articles Daily in the Life Science Industry

TORONTO, ON--(Marketwired - October 26, 2015) - Check out all news stories here: http://xtalks.com/News.ashx. Subscribe to our weekly newsletter: http://register.xtalks.com/newsblogs.

Generic Form of Turing's Pricey Drug, Daraprim, Could Cost $1 Per Pill -- http://ow.ly/TQnAj
(Oct 23) Imprimis -- a California-based pharmaceutical manufacturer -- has stepped up to the challenge and announced that it will begin offering a generic alternative to Daraprim.

Study Finds Worldwide Access To Affordable Heart Medicines Needs Improvement -- http://ow.ly/TQnCP
(Oct 23) According to research published in The Lancet, only three percent of heart disease patients worldwide, take the medications which could prevent further development of the disease.

Leptin Gene Therapy Shows Promise For Weight Loss -- http://ow.ly/TQnGu
(Oct 22) New research suggests that brain injections of the gene that encodes leptin -- known as the 'satiety hormone' -- could be more effective at helping individuals lose weight.

Daily Aspirin Could Increase Fertility -- http://ow.ly/TQnJC
(Oct 22) Researchers from the University of Utah, and the National Institute of Child Health and Human Development (NICHD), suggest that taking a daily low-dose of aspirin could increase chances of pregnancy, especially for women who have previously miscarried.

Is The Placebo Effect To Blame For The Increase in Drug Trial Failure?-- http://ow.ly/TQnO6
(Oct 21) A new study published in the journal Pain, suggests that the placebo effect has been getting stronger -- especially in the US -- and it may be the reason why so many new pharmaceuticals fail to pass their clinical trials.

Skin Cancer Prediction By Numbers -- http://ow.ly/TQnRO
(Oct 21) According to Simon Ribero, of the Department of Twin Research and Genetic Epidemiology at King's College and his colleagues, the number of moles a person has is a good indicator of their risk of developing melanoma.

FDA Approves Specific Reversal Agent for Pradaxa -- http://ow.ly/TQnW5
(Oct 20) According to a press release from the US Food and Drug Administration (FDA), the agency has granted accelerated approval for Boehringer Ingelheim's Praxbind (idarucizumab) -- a specific reversal agent for the company's anticoagulant, Pradaxa (dabigatran).

Blood Test for Alzheimer's Disease On The Horizon -- http://ow.ly/TQnZF
(Oct 20) A blood test for early detection of Alzheimer's disease is nearing completion at the Rowan University School of Osteopathic Medicine, in New Jersey.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx.

Contact Information